SLC28A3: A Potential Drug Target and Biomarker (G64078)

Target Name: SLC28A3

NCBI ID: G64078

SLC28A3

SLC28A3: A Potential Drug Target and Biomarker

Solute Carrier Family 28 (SLC28) is a family of transmembrane proteins that play a crucial role in various physiological processes in the body. One of the members of this family, SLC28A3, has been identified as a potential drug target and biomarker. In this article, we will explore the biology of SLC28A3, its potential as a drug target, and its potential as a biomarker for various diseases.

SLC28A3: Structure and Function

SLC28A3 is a member of the SLC28 family, which consists of six structurally similar proteins (1-6). SLC28A3 has a unique Transmembrane-Protein (TMP) domain, which is responsible for its transmembrane properties and plays a key role in the regulation of ion channels. SLC28A3 also has a unique N-terminal region, which contains a Glycophosphate (GPT) domain and is involved in protein-protein interactions.

SLC28A3 is a 28kDa protein that has a calculated pI of 8.0. It is expressed in various tissues and cells of the body, including the brain, heart, and gastrointestinal tract. SLC28A3 is involved in various physiological processes, including ion homeostasis, intracellular signaling, and neurotransmission.

Potential Drug Target

SLC28A3 has been identified as a potential drug target due to its unique structure and function. One of the key features of SLC28A3 is its TMP domain, which is known to be involved in protein-protein interactions and is thought to play a role in modulating the activity of other proteins. Additionally, SLC28A3 has a unique N-terminal region that contains a GPT domain, which is known to be involved in protein-protein interactions and is thought to play a role in modulating the activity of other proteins.

SLC28A3 has been shown to interact with several protein partners, including the protein known as TrkB (9) and the protein known as FAK. TrkB is a G protein-coupled receptor that plays a role in neurotransmission, while FAK is a protein that is involved in cell signaling.

SLC28A3 has also been shown to play a role in modulating the activity of several intracellular signaling pathways, including the signaling pathway known as the T-cell signaling pathway. This suggests that SLC28A3 may be a useful drug target for diseases that are characterized by the disruption of these signaling pathways.

Potential Biomarker

SLC28A3 has also been identified as a potential biomarker for several diseases. For example, SLC28A3 has been shown to be involved in the regulation of ion homeostasis, which is important for maintaining the proper functioning of the body's cells and tissues. Additionally, SLC28A3 has been shown to play a role in modulating the activity of intracellular signaling pathways, which are important for the regulation of cellular behavior.

SLC28A3 has also been shown to be involved in the regulation of neurotransmission, which is important for the proper functioning of the nervous system. This suggests that SLC28A3 may be a useful biomarker for diseases

Protein Name: Solute Carrier Family 28 Member 3

Functions: Sodium-dependent, pyrimidine- and purine-selective (PubMed:11032837, PubMed:15861042, PubMed:16446384, PubMed:17140564, PubMed:21998139). Involved in the homeostasis of endogenous nucleosides (PubMed:11032837, PubMed:15861042). Exhibits the transport characteristics of the nucleoside transport system cib or N3 subtype (N3/cib) (with marked transport of both thymidine and inosine) (PubMed:11032837). Employs a 2:1 sodium/nucleoside ratio (PubMed:11032837). Transports uridine (PubMed:21795683). Also able to transport gemcitabine, 3'-azido-3'-deoxythymidine (AZT), ribavirin and 3-deazauridine (PubMed:11032837, PubMed:17140564)

The "SLC28A3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC28A3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets